9 results match your criteria: "and St. John Hospital[Affiliation]"
Contemp Clin Trials
July 2023
Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.
Alcohol use and violent behaviors among youth are associated with morbidity and mortality. An emergency department (ED) visit provides an opportunity to initiate prevention efforts. Despite promising findings from our single session SafERteens brief intervention (BI), impact is limited by modest effect sizes, with data lacking on optimal boosters to enhance effects.
View Article and Find Full Text PDFInt J Clin Pharm
February 2019
Department of Pharmacy Practice, Wayne State University and St. John Hospital and Medical Center, 259 Mack Avenue, Detroit, MI, 48201, USA.
N Engl J Med
June 2016
From the Hospital Outcomes Program of Excellence, Veterans Affairs (VA) Ann Arbor Healthcare System (S.S., M.T.G., S.L.K., D.R., K.E.F.), the Department of Internal Medicine, University of Michigan (UM) Medical School (S.S., M.T.G., S.L.K., M.A.M.R.), and the VA/UM Patient Safety Enhancement Program (S.S., M.T.G., S.L.K., M.A.M.R., D.R., K.E.F.), Ann Arbor, the Michigan Health and Hospital Association, Okemos (S.R.W., B.M.-L., M.M.), and St. John Hospital and Medical Center, Detroit (M.G.F.) - all in Michigan; the Health Research and Educational Trust, Chicago (B.S.E., K.F.); the Centers for Disease Control and Prevention, Atlanta (C.V.G.); and the Agency for Healthcare Research and Quality, Rockville, MD ( J.B.).
Background: Catheter-associated urinary tract infection (UTI) is a common device-associated infection in hospitals. Both technical factors--appropriate catheter use, aseptic insertion, and proper maintenance--and socioadaptive factors, such as cultural and behavioral changes in hospital units, are important in preventing catheter-associated UTI.
Methods: The national Comprehensive Unit-based Safety Program, funded by the Agency for Healthcare Research and Quality, aimed to reduce catheter-associated UTI in intensive care units (ICUs) and non-ICUs.
Rev Cardiovasc Med
April 2015
Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, The Heart Hospital, Plano TX.
Excess adiposity and obesity are the root cause of at least 27 diseases that cause considerable lifelong morbidity and, in many scenarios, eventual cardiovascular mortality. The human body has the ability to increase the number and size of its adipocytes by approximately 10-fold over the course of a lifetime. As fat mass increases, its blood supply, supporting cells, tissue structure, and local and systemic hormonal control also increase.
View Article and Find Full Text PDFMaturitas
September 2014
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University and St. John Hospital and Medical Center, Detroit, MI, United States. Electronic address:
Am J Health Syst Pharm
December 2013
Melissa Lipari, Pharm.D., BCACP, is Assistant Professor; Harpreet Benipal, Pharm.D., is a 2013 graduate; and Pramodini Kale-Pradhan, Pharm.D., is Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, and St. John Hospital and Medical Center, Detroit, MI.
Purpose: The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing chronic obstructive pulmonary disease (COPD)-are reviewed.
Summary: Roflumilast (Daliresp, Forest Pharmaceuticals) is an oral phosphodiesterase-4 (PDE-4) inhibitor that targets inflammatory cells involved in triggering COPD exacerbations. The only PDE-4 inhibitor approved by the Food and Drug Administration, roflumilast is available in 500-μg tablets to be administered once daily.
Prim Care Companion J Clin Psychiatry
January 2004
Neuroscience Education Institute, University of California, San Diego; Bay Pointe Depression Clinic, New Baltimore, the Department of Family Practice, Mt. Clemens General Hospital, Mt. Clemens, and St. John Hospital, Detroit, Mich.; and GlaxoSmithKline, Research Triangle Park, N.C.
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
October 1997
The Arrhythmia Center/Sinai Hospital and St. John Hospital, Detroit, Michigan 48235, USA.
Introduction: Implantable cardioverter defibrillators (ICDs) are occasionally used in presumed high-risk patients with electrocardiographically undocumented syncope, although the incidence of ventricular tachyarrhythmias in this population is not well defined.
Methods And Results: We studied 33 consecutive patients receiving an ICD (67% nonthoracotomy and 70% tiered therapy) after electrophysiologic testing for unmonitored "syncope" (n = 29) or "near-syncope" (n = 4). Atherosclerotic heart disease was present in 24 (73%); mean left ventricular ejection fraction (LVEF) was 0.
Pharmacotherapy
September 1997
Department of Pharmacy Practice, Wayne State University, and St. John Hospital and Medical Center, Detroit, Michigan 48236, USA.
Plasmapheresis (PP) is being increasingly performed to treat a number of infectious, immunologic, metabolic, and inherited illnesses. In this procedure, plasma and cellular components of blood are separated, and all solutes in plasma, including drugs, can be removed. The effects of PP on the pharmacokinetics of drugs administered therapeutically and taken in overdose are evolving.
View Article and Find Full Text PDF